Monitor the clinical pilot launch within 90 days and the distributor's ability to meet undisclosed minimum revenue thresholds within 30 months. The activist SC 13D filing 28 days prior suggests potential pressure for strategic action — watch for further activist escalation or additional partnership announcements.
Price Chart
Executive Summary
Nexalin Technology signed a definitive 10-year exclusive distribution and local manufacturing agreement with Inovanexa Medical Technologies S.A. (in formation) for the Nexalin Sync neurostimulation device across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador, and Venezuela. The deal includes a binding initial purchase order for 10 devices, a clinical pilot targeted within 90 days, and a distributor-funded local manufacturing facility in Brazil that will generate per-device compensation and per-disposable royalties for Nexalin at zero capital cost. The agreement was filed 28 days after an activist SC 13D filing by Greenlight Ventures, LLC, suggesting potential strategic pressure behind the deal.
Key Financial Metrics
Key Facts
- 10-year exclusive distribution agreement covering 7 South American countries with >300 million people
- Binding initial purchase order for 10 Nexalin Sync devices at signing
- Clinical pilot program in Brazil targeted to launch within 90 days
- Distributor must establish local manufacturing facility in Brazil at its own cost upon purchase of first 30 devices
- Nexalin retains all IP and supplies encrypted circuit boards exclusively
- Per-device compensation and per-disposable royalty on locally manufactured products
- Distributor must generate minimum aggregate revenues to Nexalin within first 30 months to maintain exclusivity
- Agreement filed 28 days after activist SC 13D filing by Greenlight Ventures, LLC
Financial Impact
Initial binding order for 10 devices at undisclosed tiered pricing; potential recurring revenue from per-device compensation and per-disposable royalties on locally manufactured products; minimum revenue thresholds for exclusivity not disclosed
Risk Factors
- Distributor is a company in formation with no operating history with Nexalin products
- Only 10 devices are under binding purchase order; no guarantee of further orders
- Local manufacturing facility requires distributor to fund entirely at its own cost — execution risk
- Regulatory approvals currently held by third-party BRH; transfer to distributor is conditional on performance
- Activist SC 13D filing may signal dissatisfaction or push for further strategic changes
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-010685 |
| Document: nexalintec_8k.htm | 0001829126-26-010685 |
| Document: nexalintec_ex99-1.htm | 0001829126-26-010685 |
| Document: 0001829126-26-010685-index-headers.html | 0001829126-26-010685 |
| Document: 0001829126-26-010685-index.html | 0001829126-26-010685 |
| Document: 0001829126-26-010685.txt | 0001829126-26-010685 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | EFFECT | $2.35 | awaiting T+20 | — | $1.71 (+27.23%) |
Oct 8, 2026 18d ago | S-1/A | $3.63 | awaiting T+20 | — | $1.71 (+52.89%) |
Oct 1, 2026 25d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Oct 1, 2026 25d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Sep 2, 2026 7w ago | 8-K | $5.36 $4.28 | ▼ −20.15% | ▼ −19.03% | $1.71 (−68.10%) |
Aug 27, 2026 8w ago | 8-K | $0.2548 $0.1463 | ▼ −42.57% | ▼ −42.60% | $1.71 (+571.11%) |
Aug 17, 2026 10w ago | 8-K | $0.3400 $0.1617 | ▲ +52.45% | ▲ +50.47% | $1.71 (−402.94%) |
Jun 10, 2026 19w ago | Press Release | $0.4590 $0.4607 | ▲ +0.37% | ▼ −3.70% | $1.71 (+272.55%) |
May 19, 2026 22w ago | 8-K | $0.3350 $0.3680 | ▲ +9.85% | ▲ +9.11% | $1.71 (+410.45%) |
May 19, 2026 22w ago | Press Release | $0.3210 $0.3930 | ▲ +22.43% | ▲ +21.44% | $1.71 (+432.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers